2021
Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence
Schultheis A, Sanchez M, Pedersen S, Kyriakides T, Ho YC, Kluger Y, Springer SA. Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence. Contemporary Clinical Trials Communications 2021, 24: 100866. PMID: 34825103, PMCID: PMC8605182, DOI: 10.1016/j.conctc.2021.100866.Peer-Reviewed Original ResearchOpioid use disorderHIV-1 persistenceHIV persistenceCohort studyHIV infectionMedication treatmentLimited bloodUse disordersProviral landscapeDSM-5 opioid-use disordersExtended-release naltrexoneProspective cohort studyHIV-1 expressionPartial agonist buprenorphineLongitudinal studyHIV continuumMonth 3Clonal expansion dynamicsMOUDDifferential biological effectsStudy participantsHIVMolecular virologyBloodBuprenorphine
2019
Analysis of the Impact of Antiretroviral Drug Changes on Survival of Patients with Advanced-Stage AIDS with Multidrug-Resistant HIV Infection
Ma R, Jung TH, Peduzzi PN, Brown ST, Kyriakides TC. Analysis of the Impact of Antiretroviral Drug Changes on Survival of Patients with Advanced-Stage AIDS with Multidrug-Resistant HIV Infection. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2019, 18: 2325958219849101. PMID: 31272313, PMCID: PMC6748500, DOI: 10.1177/2325958219849101.Peer-Reviewed Original ResearchConceptsDrug changesCox proportional hazards regression modelKaplan-Meier survival techniqueMultidrug-resistant HIV infectionProportional hazards regression modelsAdvanced-stage AIDSDrug regimen changesSurvival of patientsHazards regression modelsAntiretroviral clinical trialsClinical biomarker dataCause mortalityMedication changesARV regimenHIV infectionImproved survivalRegimen changeClinical outcomesNonclinical reasonsClinical trialsBiomarker changesTreatment historyMultidrug resistanceTherapy strategiesPatients
2011
Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial
Holodniy M, Brown ST, Cameron DW, Kyriakides TC, Angus B, Babiker A, Singer J, Owens DK, Anis A, Goodall R, Hudson F, Piaseczny M, Russo J, Schechter M, Deyton L, Darbyshire J, . Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial. PLOS ONE 2011, 6: e14764. PMID: 21483491, PMCID: PMC3069000, DOI: 10.1371/journal.pone.0014764.Peer-Reviewed Original ResearchConceptsRe-treatment optionsART interruptionHIV infectionPrimary outcomeRetreatment optionsMultidrug resistanceAdvanced HIV diseaseAntiretroviral treatment interruptionARV treatment failurePrior AIDS diagnosisResistant HIV InfectionMedian CD4 countPrimary composite outcomeSerious adverse eventsMean viral loadBest medical managementOPTIMA trialCD4 countOpen labelTreatment interruptionAdverse eventsComposite outcomeFirst AIDSHIV diseaseAntiretroviral treatment